Unknown

Dataset Information

0

Vaccination with Vaxfectin(®) adjuvanted SIV DNA induces long-lasting humoral immune responses able to reduce SIVmac251 Viremia.


ABSTRACT: We evaluated the immunogenicity and efficacy of Vaxfectin(®) adjuvanted SIV DNA vaccines in mice and macaques. Vaccination of mice with Vaxfectin(®) adjuvanted SIV gag DNA induced higher humoral immune responses than administration of unadjuvanted DNA, whereas similar levels of cellular immunity were elicited. Vaxfectin(®) adjuvanted SIVmac251 gag and env DNA immunization of rhesus macaques was used to examine magnitude, durability, and efficacy of humoral immunity. Vaccinated macaques elicited potent neutralizing antibodies able to cross-neutralize the heterologous SIVsmE660 Env. We found remarkable durability of Gag and Env humoral responses, sustained during ~2 y of follow-up. The Env-specific antibody responses induced by Vaxfectin(®) adjuvanted env DNA vaccination disseminated into mucosal tissues, as demonstrated by their presence in saliva, including responses to the V1-V2 region, and rectal fluids. The efficacy of the immune responses was evaluated upon intrarectal challenge with low repeated dose SIVmac251. Although 2 of the 3 vaccinees became infected, these animals showed significantly lower peak virus loads and lower chronic viremia than non-immunized infected controls. Thus, Vaxfectin(®) adjuvanted DNA is a promising vaccine approach for inducing potent immune responses able to control the highly pathogenic SIVmac251.

SUBMITTER: Kulkarni V 

PROVIDER: S-EPMC3906391 | BioStudies | 2013-01-01

REPOSITORIES: biostudies

Similar Datasets

2020-01-01 | S-EPMC7329227 | BioStudies
2013-01-01 | S-EPMC3906392 | BioStudies
1000-01-01 | S-EPMC2734879 | BioStudies
2020-01-01 | S-EPMC7158742 | BioStudies
2019-12-10 | GSE141707 | GEO
2002-01-01 | S-EPMC136751 | BioStudies
2012-01-01 | S-EPMC3601136 | BioStudies
2019-01-01 | S-EPMC6450945 | BioStudies
2015-01-01 | S-EPMC4653134 | BioStudies
1000-01-01 | S-EPMC5286877 | BioStudies